Michael E. Stokes
Researcher
University of Arkansas for Medical Sciences
faculty
Research Areas
Links
Is this your profile? Verify and claim your profile
Biography and Research Information
OverviewAI-generated summary
Michael E. Stokes is a faculty member at the University of Arkansas for Medical Sciences. His research group focuses on the development of small molecule inhibitors targeting key cellular pathways involved in disease. Recent work includes the development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for the treatment of COVID-19.
Stokes also investigates the role of the PERK pathway in cancer progression and treatment resistance. Studies have explored PERK inhibition as a strategy to block metastatic spread and sensitize renal cell carcinoma models to antiangiogenic tyrosine kinase inhibitors. His group has also optimized a novel series of PERK inhibitors, including HC-5404, which has been evaluated in a Phase 1a study for advanced solid tumors. Further research indicates that PERK inhibition may decrease the risk of autoimmune diabetes in mice.
Additional research interests include analyzing real-world use patterns and effectiveness of specific cancer therapies, such as sacituzumab govitecan for metastatic triple-negative breast cancer. Stokes has also examined healthcare utilization and costs associated with different treatment modalities for drug-resistant epilepsy. He has published over 120 works, with an h-index of 21 and over 3,100 citations.
Metrics
- h-index: 21
- Publications: 122
- Citations: 3,105
Selected Publications
- Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States (2024) DOI
- Inhibition of the eukaryotic initiation factor-2α kinase PERK decreases risk of autoimmune diabetes in mice (2024) DOI
- A multicenter, open-label, phase 1a study of HC-5404 in patients with advanced solid tumors. (2024) DOI
- Supplementary Table S5 from A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response–Dependent Survival of Quiescent Cancer Cells (2023) DOI
- Supplementary Table S1 from A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response–Dependent Survival of Quiescent Cancer Cells (2023) DOI
- Supplementary Table S6 from A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response–Dependent Survival of Quiescent Cancer Cells (2023) DOI
- Supplementary Figure S2 from A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response–Dependent Survival of Quiescent Cancer Cells (2023) DOI
- Supplementary Figure S3 from A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response–Dependent Survival of Quiescent Cancer Cells (2023) DOI
- Supplementary Table S3 from A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response–Dependent Survival of Quiescent Cancer Cells (2023) DOI
- Supplementary Table S6 from A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response–Dependent Survival of Quiescent Cancer Cells (2023) DOI
- Supplementary Figure S2 from A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response–Dependent Survival of Quiescent Cancer Cells (2023) DOI
- Supplementary Table S7 from A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response–Dependent Survival of Quiescent Cancer Cells (2023) DOI
- Supplementary Figure S1 from A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response–Dependent Survival of Quiescent Cancer Cells (2023) DOI
- Supplementary Table S5 from A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response–Dependent Survival of Quiescent Cancer Cells (2023) DOI
- Supplementary Table S1 from A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response–Dependent Survival of Quiescent Cancer Cells (2023) DOI
Similar Researchers
Based on overlapping research topics